Zhimin Shao

4.9k total citations
90 papers, 1.8k citations indexed

About

Zhimin Shao is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhimin Shao has authored 90 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 42 papers in Cancer Research and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhimin Shao's work include Breast Cancer Treatment Studies (32 papers), HER2/EGFR in Cancer Research (31 papers) and Cancer Treatment and Pharmacology (26 papers). Zhimin Shao is often cited by papers focused on Breast Cancer Treatment Studies (32 papers), HER2/EGFR in Cancer Research (31 papers) and Cancer Treatment and Pharmacology (26 papers). Zhimin Shao collaborates with scholars based in China, United States and Taiwan. Zhimin Shao's co-authors include Biyun Wang, Jinsong Lu, Xichun Hu, Zhenzhou Shen, Yiwei Jiang, Wenjin Yin, Kunwei Shen, Leiping Wang, Yi‐Zhou Jiang and Jiong Wu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Zhimin Shao

88 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhimin Shao China	22	1.1k	557	557	516	290	90	1.8k
Akihiko Shimomura Japan	22	1.1k 1.0×	536 1.0×	537 1.0×	751 1.5×	331 1.1×	132	2.0k
Yang Luo China	21	989 0.9×	476 0.9×	529 0.9×	371 0.7×	236 0.8×	135	1.5k
Séverine Guiu France	24	1.1k 1.0×	464 0.8×	751 1.3×	399 0.8×	356 1.2×	78	1.9k
Arlene Berman United States	22	1.3k 1.1×	474 0.9×	534 1.0×	614 1.2×	284 1.0×	47	2.4k
Federico Piacentini Italy	23	1.3k 1.2×	517 0.9×	718 1.3×	386 0.7×	328 1.1×	115	1.9k
Jin‐Hee Ahn South Korea	25	938 0.8×	821 1.5×	484 0.9×	549 1.1×	295 1.0×	115	1.9k
Ying Fan China	23	1.1k 1.0×	513 0.9×	697 1.3×	542 1.1×	194 0.7×	120	1.7k
Sònia Pernas Spain	20	1.1k 1.0×	447 0.8×	545 1.0×	413 0.8×	312 1.1×	109	1.6k
Luc Cabel France	24	1.2k 1.0×	599 1.1×	924 1.7×	487 0.9×	177 0.6×	81	1.9k
Jinming Yu China	19	1.2k 1.1×	671 1.2×	456 0.8×	579 1.1×	249 0.9×	66	2.3k

Countries citing papers authored by Zhimin Shao

Since Specialization

Citations

This map shows the geographic impact of Zhimin Shao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhimin Shao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhimin Shao more than expected).

Fields of papers citing papers by Zhimin Shao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhimin Shao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhimin Shao. The network helps show where Zhimin Shao may publish in the future.

Co-authorship network of co-authors of Zhimin Shao

This figure shows the co-authorship network connecting the top 25 collaborators of Zhimin Shao. A scholar is included among the top collaborators of Zhimin Shao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhimin Shao. Zhimin Shao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Junjie, Zhihua Wang, Liangan Chen, et al.. (2025). Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial. Annals of Oncology. 36(6). 651–659. 9 indexed citations

Robertson, J.F.R., Zhimin Shao, Shinzaburo Noguchi, et al.. (2025). Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial. Journal of Clinical Oncology. 43(13). 1539–1545. 3 indexed citations

Pan, Zhe, Li Zhang, Wei Shi, et al.. (2024). Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism. Advanced Science. 12(5). e2413103–e2413103. 1 indexed citations

Bai, Qianming, Ming Li, Shuling Zhou, et al.. (2024). Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns. Journal of Clinical Pathology. 78(8). 540–547. 3 indexed citations

Hu, Shu‐Yuan, et al.. (2023). Destabilization of microrchidia family CW‐type zinc finger 2 via the cyclin‐dependent kinase 1‐chaperone‐mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule‐targeting agents. Clinical and Translational Medicine. 13(3). e1210–e1210. 6 indexed citations

Shao, Zhimin, Ling‐Ming Tseng, Chiun‐Sheng Huang, et al.. (2021). Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study. Japanese Journal of Clinical Oncology. 51(3). 345–353. 2 indexed citations

Xu, Binghe, Wei Li, Qingyuan Zhang, et al.. (2020). Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Research and Treatment. 182(3). 689–697. 29 indexed citations

Zhang, Ying, et al.. (2020). The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population. Surgery. 168(6). 1115–1121. 1 indexed citations

Guo, Rong, Yonghui Su, Jing Si, et al.. (2020). A nomogram for predicting axillary pathologic complete response in hormone receptor–positive breast cancer with cytologically proven axillary lymph node metastases. Cancer. 126(S16). 3819–3829. 12 indexed citations

10.

Zhu, Xinyi, Tian Tian, Miao Ruan, et al.. (2018). Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations. Journal of Breast Cancer. 21(3). 297–297. 4 indexed citations

11.

Toi, Masakazu, Zhimin Shao, Sara A. Hurvitz, et al.. (2017). Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Research. 19(1). 47–47. 17 indexed citations

12.

Harbeck, Nadia, Chiun‐Sheng Huang, Sara A. Hurvitz, et al.. (2016). Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. The Lancet Oncology. 17(3). 357–366. 105 indexed citations

13.

Chen, Ying, Jiajian Chen, Jiaying Chen, et al.. (2014). [Current trends of breast reconstruction after mastectomy for breast cancer patients in China: a survey report].. PubMed. 36(11). 851–7. 12 indexed citations

14.

Cristofanilli, Massimo, Stephen Johnston, Alexey Manikhas, et al.. (2012). A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Research and Treatment. 137(2). 471–482. 50 indexed citations

15.

Jiang, Yiwei, Wenjin Yin, Liheng Zhou, et al.. (2012). First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis. PLoS ONE. 7(3). e32474–e32474. 16 indexed citations

16.

Yin, Wenjin, Yiwei Jiang, Zhenzhou Shen, Zhimin Shao, & Jinsong Lu. (2011). Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials. PLoS ONE. 6(6). e21030–e21030. 120 indexed citations

17.

Luo, Jianmin, et al.. (2010). Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)‐overexpressing breast cancer cells and activity of bortezomib against lapatinib‐resistant breast cancer cells. Cancer Science. 101(10). 2220–2226. 11 indexed citations

18.

Chen, Wen, et al.. (2009). An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer. Value in Health. 12. S82–S84. 34 indexed citations

19.

Shao, Zhimin. (2008). BRCA1 and BRCA2 deleterious mutation in 219 Han Chinese hereditary breast cancer patients. Zhongguo aizheng zazhi. 1 indexed citations

20.

Wu, Jiong, et al.. (1997). In situ labeling apotosis in breast cancer as related to prognosis. Chinese Journal of Cancer Research. 9(3). 213–216. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact